PMID- 35117924
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep
TI  - Clinicopathological significance of Sox10 expression in triple-negative breast 
      carcinoma.
PG  - 5603-5613
LID - 10.21037/tcr-20-2634 [doi]
AB  - BACKGROUND: This study aimed to investigate the SRY-related higll-mobility-group 
      box 10 (Sox10) expression in the pathological diagnosis of triple-negative breast 
      cancer (TNBC). Furthermore, its correlation with the clinicopathological 
      characteristics and disease-free survival rate in patients with TNBC was also 
      evaluated to identify the diagnostic utility of Sox10 as a reliable biomarker for 
      the diagnosis and prognosis of TNBC. METHODS: Using immunohistochemistry (IHC), 
      we identified the expression of Sox10, GATA binding protein 3 (GATA-3), forkhead 
      box protein A1 (FOXA1), gross cystic disease fluid protein (GCDFP15), and 
      mammaglobin (MGB) in 376 cases of primary invasive breast cancer, and 77 cases of 
      metastatic breast cancer. The expression of Sox10 in different molecular subtypes 
      of primary invasive breast cancer and metastatic breast cancer were also 
      compared. Furthermore, the correlation between Sox10 expression and 
      clinicopathological parameters and disease-free survival (DFS) of patients with 
      primary TNBC were also analyzed. RESULTS: Expression of Sox10 was only detected 
      in the myoepithelial cells of normal breast tissue, but not in any other types of 
      cells, including luminal cells and fibroblasts. The positive rate of Sox10 in 
      primary and metastatic TNBC was significantly higher than that in luminal types 
      and human epidermal growth factor receptor 2 (HER2) overexpressed type. The 
      sensitivity and specificity of Sox10 expression in primary TNBC and metastatic 
      TNBC were significantly lower than GATA-3, significantly higher than FOXA1, 
      GCDFP15, and MGB (P<0.001, P=0.0004, P=0.0064, P=0.0229, respectively). In 71 
      cases of primary TNBC, a higher expression rate of Sox10 was significantly 
      associated with high-grade tumors, late-stage tumors, and tumors with involvement 
      of four or more lymph node metastases (P=0.0145, P=0.0105, P=0.0249, 
      respectively). CONCLUSIONS: Sox10 may be used as a novel reliable putative marker 
      for the diagnosis of TNBC. Notably, Sox10 combined with GATA-3 expression may 
      serve as a supplementary differential diagnostic biomarker for primary and 
      metastatic TNBC. Besides, Sox10 may be a good predictor of the prognosis of 
      primary and metastatic TNBC. This study also highlights the significance of 
      targeting Sox10 as a promising potential therapeutic target gene for TNBC 
      therapy.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - Jin, Linfang
AU  - Jin L
AD  - Department of Thyroid and Mammary Surgery, The Second affiliated Hospital of 
      Soochow University, Suzhou, China.
AD  - Department of Pathology, Affiliated Hospital of Jiangnan University (Wuxi Fourth 
      People's Hospital), Wuxi, China.
FAU - Qin, Chenglin
AU  - Qin C
AD  - Department of General Surgery, The First People's Hospital of Yancheng, Yancheng, 
      China.
FAU - Qi, Xiaowei
AU  - Qi X
AD  - Department of Pathology, Affiliated Hospital of Jiangnan University (Wuxi Fourth 
      People's Hospital), Wuxi, China.
FAU - Hong, Tingting
AU  - Hong T
AD  - Department of Oncology, Affiliated Hospital of Jiangnan University (Wuxi Fourth 
      People's Hospital), Wuxi, China.
FAU - Yang, Xiaodong
AU  - Yang X
AD  - Department of Gastrointestinal Surgery, The Second affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Zhu, Xun
AU  - Zhu X
AD  - Department of Thyroid and Mammary Surgery, The Second affiliated Hospital of 
      Soochow University, Suzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8797416
OTO - NOTNLM
OT  - SRY-related higll-mobility-group box 10 (Sox10)
OT  - Triple-negative breast cancer (TNBC)
OT  - clinicopathological characteristics
OT  - disease-free survival (DFS)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-20-2634). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/09/01 00:00
MHDA- 2020/09/01 00:01
PMCR- 2020/09/01
CRDT- 2022/02/04 05:52
PHST- 2020/07/08 00:00 [received]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2022/02/04 05:52 [entrez]
PHST- 2020/09/01 00:00 [pubmed]
PHST- 2020/09/01 00:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - tcr-09-09-5603 [pii]
AID - 10.21037/tcr-20-2634 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 Sep;9(9):5603-5613. doi: 10.21037/tcr-20-2634.